SynAct Pharma: Interim report January-March 2021

“The first three months have indeed given a strong and convincing start of the new year to SynAct Pharma, when we continued to make significant progress on our projects and put the company in a unique position to be a leader in resolution therapy, a new method for treating inflammation and autoimmune diseases,” said Jeppe Øvlesen, CEO

Summary of interim report

2021-01-01 – 2021-03-31 (first quarter)

  • Consolidated net sales amounted to 0 (0) TSEK.
  • The Group’s profit before tax amounted to -14,070 ( -3,822) TSEK.
  • The Group’s earnings per share amounted to -0.46 (-0.14).
  • The average number of shares for the period was 25,366,295.

“SynAct Pharma AB” means the parent company SynAct Pharma AB with corporate registration number 559058-4826. The “Company” or “SynAct” means the Group, i.e. SynAct Pharma AB and its wholly owned subsidiary SynAct Pharma ApS.


  • Earnings per share: Profit for the period divided by the average number of shares outstanding in the period.
  • Equity/assets ratio: Equity divided by total capital.

Significant events in Q1 2021

  • On January 11, board member and CSO Thomas Jonassen and CEO Jeppe Øvlesen carried out a restructuring in which the respective holdings of shares in SynAct have transferred to the newly formed company BioInvest ApS.
  • On January 26, SynAct Thomas Boesen was appointed Chief Operating Officer
  • On February 4, it was announced that SynAct is preparing to move to Nasdaq Stockholm
  • On February 5, it was announced that SynAct had completed a directed share issue of SEK 80 million
  • On February 11, James Knight was appointed Chief Business Officer
  • On March 18, it was announced that SynAct has started dosing in Part 2 of the Phase II clinical trial with AP1189 in Covid-19 infected patients

Significant events after the end of the period

  • On April 13, it was announced that SynAct is strengthening its IP portfolio and receiving “Intention to Grant” from the European Patent Office for a central patent covering AP1189
  • On April 19, It was announced that SynAct shareholders are proposing Marina Bozilenko as a new board member
  • On April 30, It was announced that SynAct is attending Kempen’s Virtual Life Sciences Conference
  • On May 4, it was announced that SynAct is expanding the BEGIN study with AP1189 in patients with rheumatoid arthritis
  • On May 4, it was announced that SynAct’s Board of Directors and management will extend its lock-up period

The information was submitted, through the agency of the contact persons below, for publication on May 5, 2021.

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen                                                                                Thomas Jonassen

CEO, SynAct Pharma AB                                                               CSO, SynAct Pharma AB

Phone: +45 28 44 75 67                                                                 Phone: +45 40 15 66 69

Mail: [email protected]                                                        Mail: [email protected]